Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Friday,RTT News reports. Wedbush currently has a $23.00 price objective on the stock.

A number of other research firms also recently issued reports on YMAB. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. Finally, HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $6.89 on Friday. The firm’s 50 day simple moving average is $10.32 and its 200 day simple moving average is $12.13. Y-mAbs Therapeutics has a one year low of $6.84 and a one year high of $20.90. The company has a market cap of $308.60 million, a PE ratio of -12.76 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. Equities research analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp lifted its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after buying an additional 405,169 shares during the period. Caligan Partners LP lifted its position in Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after buying an additional 613,175 shares during the period. Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares during the period. Dimensional Fund Advisors LP lifted its position in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares during the period. Finally, Millennium Management LLC lifted its position in Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares during the period. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.